-
721“…Particularly, the percentage of respondents who are willing to get vaccinated with Pfizer, Moderna and AstraZeneca dominates that of those who are willing to get vaccinated with Sinopharm, Janssen and Sputnik V vaccines. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
722“…AVAILABILITY AND IMPLEMENTATION: The Nextflow workflow, the Singularity image and a test dataset are available at https://github.com/AstraZeneca/detectIS. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
723por Horváth, Judit K., Ferenci, Tamás, Ferenczi, Annamária, Túri, Gergő, Röst, Gergely, Oroszi, Beatrix“…While the picture is different in each age group, the waning of immunity is apparent for all vaccines, especially in the younger age groups and the Sinopharm, Sputnik-V, and AstraZeneca vaccines, which performed similarly. This is clearly reversed by booster doses, more prominent for those three vaccines, where the decline in protection is more evident. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
724por Allas, Gewil Daniella Olipas, Arizala, Joekeem Del Rosario, Manalo, Rafael Vincent Mercado“…Adenoviral-based vaccines such as ChadoX1 CoV-19 (AstraZeneca) and Ad26.COV2.S (J&J) were developed to prevent infection and reduce hospitalization or death in Coronavirus Disease 2019 (COVID-19) patients. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
725por Albers, Jacob R., Brown, Jeffrey B., Charkowick, Shaun V., Ram, Natasha, Klocksieben, Farina A., Kumar, Ambuj“…Results from Pfizer-BioNTech mRNA, Moderna-US NIH mRN-1273, AstraZeneca-Oxford ChAdOx1 nCov-19, Gamaleya GamCovidVac (Sputnik V), and Ad26.COV2.S Johnson & Johnson vaccines were included. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
726por Wang, Ling-Uei, Chen, Fang-Ting, Wang, Jia-Kang, Huang, Tzu-Lun, Chang, Pei-Yao, Chen, Yun-Ju, Hsu, Yung-Ray“…We present a case series of 11 patients presenting with ocular manifestations relevant to vaccine-associated autoimmune response within 6 weeks after the vaccination of the Oxford–AstraZeneca, the Moderna, and Pfizer-BioNTech vaccines at the main tertiary referral center in the most populated and most vaccinated city in Taiwan. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
727por Alcorta-Nuñez, Fernando, Pérez-Ibave, Diana Cristina, Burciaga-Flores, Carlos Horacio, Garza, Miguel Ángel, González-Escamilla, Moisés, Rodríguez-Niño, Patricia, González-Guerrero, Juan Francisco, Alcorta-Garza, Adelina, Vidal-Gutiérrez, Oscar, Ramírez-Correa, Genaro A., Garza-Rodríguez, María Lourdes“…We performed a real-world evidence study to detect NAs that confer protection against SARS-CoV-2 after the application of five vaccines (Pfizer/BioNTech, AstraZeneca, Sinovac, Moderna, and CanSino) in the Mexican population. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
728por Osei, Racheal, Ahmed, Saad, Morrow, David, Hamid, Sarbast, Hawkins, Peter, Mohan, Mahalakshmi“…Administration of the ChAdOx1 nCoV-19 (AstraZeneca) vaccination has recently been associated with rare, unusual cases of thrombotic events. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
729por Messina, Nicole L., Sperotto, Mariana G., Puga, Marco A. M., da Silva, Patricia V., de Oliveira, Roberto D., Moore, Cecilia L., Pittet, Laure F., Jamieson, Tenaya, Dalcolmo, Margareth, dos Santos, Glauce, Jardim, Bruno, Lacerda, Marcus V. G., Curtis, Nigel, Croda, Julio“…We compared antibody responses to CoronaVac (Sinovac) and ChAdOx1-S (AstraZeneca-Oxford) vaccination in 874 healthcare workers in Brazil. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
730“…METHODS: A total of 5562 tweets about three vaccine brands (Sinovac, AstraZeneca, and Pfizer) were collected from 14 December 2020 to 30 December 2021. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
731por Althaqafi, Abdulhakeem, Munshi, Adeeb, Mujalled, Mohamed K, Munshi, Enas, Alhouthali, Ahmad, Alqalayta, Lama, Zahed, Hala, Bahashwan, Mariya S, Alghubayshi, Laila, Alghamdi, Ahmad“…Results The knowledge of the responders for each vaccine is as follows: Pfizer-BioNTech, 96.1%; AstraZeneca-Oxford, 66.1%; Moderna, 56.9%; and Johnson & Johnson's Janssen, 18.2%. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
732por Moll, María Elena Camacho, Martínez, Ana María Salinas, Cisneros, Benjamín Tovar, Onofre, Juan Ignacio García, Floriano, Gloria Navarrete, de León, Mario Bermúdez“…Lactating women experienced fewer local symptoms after the first or single dose (p = 0.04) and the opposite occurred after the second dose (p = 0.001). ChAdOx1 (AstraZeneca) increased the chances of developing both local and systemic symptoms after the first dose but decreased them after the second dose. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
733por Rafie, Reyhaneh Alipoor, Azimi, Leila, Armin, Shahnaz, Aghamohammadi, Amirali, Karimi, Abdollah, Fallah, Fatemeh, Khodaei, Hannan, Mansour Ghanaie, Roxana, Alebouyeh, Masoud“…Healthcare workers in Mofid Children’s hospital received three brands of vaccines: Sputnik V, Sinopharm, and AstraZeneca. RESULTS: The mean titer of anti-spike IgG was 4.3±2.29 units. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
734por Jędrzejczyk, Tadeusz, Tyrańska-Fobke, Anna, Ślęzak, Daniel, Kamińska, Weronika, Kaszubowski, Mariusz F., Bem, Agnieszka, Robakowska, Marlena“…The presented cross-sectional survey was conducted among 4622 teachers from all levels of education in public and non-public institutions who received the SARS-CoV-2 virus vaccination campaign with the vaccine from AstraZeneca as part of the NVP. The survey was conducted using an original, self-designed questionnaire prepared for this study and distributed to teachers in the form of an online survey via email. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
735
-
736por Eriksson, Mats, Nilsson, Ingemar, Kogej, Thierry, Southan, Christopher, Johansson, Martin, Tyrchan, Christian, Muresan, Sorel, Blomberg, Niklas, Bjäreland, Marcus“…The main activity sources of ChEMBL,1 GOSTAR2 and AstraZeneca’s internal system IBIS, had already been integrated in Chemistry Connect.3 For target relationships we selected human UniProtKB/Swiss-Prot4 as our primary source of a heuristic target classification. …”
Publicado 2012
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
737por Kupferberg, Aleksandra, Hager, Oliver M., Fischbacher, Urs, Brändle, Laura S., Haynes, Melanie, Hasler, Gregor“…DECLARATION OF INTEREST: G.H. received research support, consulting fees and speaker honoraria from Lundbeck, AstraZeneca, Servier, Eli Lilly, Roche and Novartis. …”
Publicado 2016
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
738por Mervin, Lewis H, Bulusu, Krishna C, Kalash, Leen, Afzal, Avid M, Svensson, Fredrik, Firth, Mike A, Barrett, Ian, Engkvist, Ola, Bender, Andreas“…We also benchmarked predictive models using a time-series split and also using bioactivities from Chemistry Connect and HTS data available at AstraZeneca, showing that orthologue bioactivity inclusion statistically improved performance. …”
Publicado 2018
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
739por Dhillon, Sohita“…Moxetumomab pasudotox-tdfk (LUMOXITI™), an anti CD22 recombinant immunotoxin, has been developed by MedImmune and its parent company AstraZeneca for the treatment of hairy cell leukaemia. …”
Publicado 2018
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
740por Handelsman, Yehuda“…Thus, current treatment recommendations include the early addition of SGLT-2 inhibitor therapy, not only in patients with established CVD, HF, and/or CKD but also in the general population of patients with T2D. Funding: AstraZeneca.…”
Publicado 2019
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto